A U.S. District Court judge in Colorado halted a 70% price cap on Amgen’s Enbrel after granting the company’s preliminary injunction. Judge Daniel Domenico said the cap could cause “economic injury” to Amgen. The ruling pauses enforcement tied to a state-level pricing measure affecting the blockbuster autoimmune therapy, and it provides immediate legal relief while the case proceeds. The decision is a reminder that payers and states are increasingly using pricing caps and administrative mechanisms, while manufacturers are pursuing injunctions to limit downstream financial impact during litigation.